In a room full of avowed capitalists, policies that sound to some like socialism are bound not to go over well.Delivering Alpharead more
At least in terms of monetary policy, Pence says should be taking after other regions who keep their benchmark interest rates near zero.Delivering Alpharead more
AT&T isn't focused on selling or divesting DirecTV, despite pressure from stakeholder Elliott Management, sources tell CNBC.Technologyread more
Amazon's purchase comes as part of its plan to convert its delivery fleet to 100% renewable energy by 2030. The e-commerce retailer already runs 40% of its fleet on renewable...Autosread more
As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
Apple's iOS 13.1 will be released on Sept. 24, six days earlier than previously announced.Technologyread more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and apply those discounts to private health plans.Health and Scienceread more
Hedge fund titan Leon Cooperman said he's concerned about a shift to the left in the political landscape, which could harm the economy and the stock market.Delivering Alpharead more
The move could bring a welcome salve to farmers caught in the crosshairs of the trade war if it results in a reopening of the market.Politicsread more
The pilot program will deliver food and beverage, over-the-counter medications and other items within minutes, the company said. Prescription deliveries will not be available.Health and Scienceread more
Check out the companies making headlines in midday trading:Market Insiderread more
It has been a good year for Johnson & Johnson shareholders, but now Goldman Sachs says investors should ring the register.
The firm on Wednesday lowered its rating for the company to sell from neutral, predicting the drugmaker's earnings growth will lag its peers during the next five years.
After the note, the stock was down 1.5 percent in early trading Wednesday.
"While JNJ's pharma division has improved and we expect accelerated growth in the near term, pressure on key franchises coupled with still slow growth of MD&D (Medical Devices & Diagnostics) and persistent pressure in consumer leaves JNJ with a below average long-term growth outlook that suggests valuation is stretched," analyst Jami Rubin wrote in a note to clients.
The company has outperformed the market this year with its shares up 17 percent through Tuesday compared with the S&P 500's 12 percent return.
Rubin predicts Johnson & Johnson will grow its earnings per share 7 percent annually during the next five years versus her 10 percent industry average forecast.
"JNJ lacks optionality for upside relative to the rest of our pharma coverage," she wrote. "The buy rated stocks in our coverage have fairly significant optionality up ahead. For instance, ABBV has a pipeline with potential for multiple best-in-class assets."
Rubin increased her price target for the company to $130 from $125, representing 4 percent downside from Tuesday's close.
"We are fully confident in our strategy to drive growth and to continue to create shareholder value in the near and long-term," said Ernie Knewitz, spokesman for Johnson & Johnson, in response to a request for comment.
— CNBC's Michael Bloom contributed to this story.